drugset / Trial / NCT03295240
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of Venetoclax in combination with FDA approved treatments Bendamustine, Rituximab and Ibrutinib (BR-I). This study will examine the effects Venetoclax has on participants when it is given in combination with BR-I.
Timeline
- Start
- 2017-09-20
- Primary completion
- 2024-01-22
- Completion
- 2024-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | 400 mg | — |
| Background | Bendamustine | Small molecule | 70 mg/m2 | — |
| Background | Bendamustine | Small molecule | 90 mg/m2 | — |
| Background | Ibrutinib | Small molecule | 560 mg | Oral |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |